Your browser doesn't support javascript.
loading
Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease.
Brosseron, Frederic; Maass, Anne; Kleineidam, Luca; Ravichandran, Kishore Aravind; González, Pablo García; McManus, Róisín M; Ising, Christina; Santarelli, Francesco; Kolbe, Carl-Christian; Häsler, Lisa M; Wolfsgruber, Steffen; Marquié, Marta; Boada, Mercè; Orellana, Adelina; de Rojas, Itziar; Röske, Sandra; Peters, Oliver; Cosma, Nicoleta-Carmen; Cetindag, Arda; Wang, Xiao; Priller, Josef; Spruth, Eike J; Altenstein, Slawek; Schneider, Anja; Fliessbach, Klaus; Wiltfang, Jens; Schott, Björn H; Bürger, Katharina; Janowitz, Daniel; Dichgans, Martin; Perneczky, Robert; Rauchmann, Boris-Stephan; Teipel, Stefan; Kilimann, Ingo; Goerss, Doreen; Laske, Christoph; Munk, Matthias H; Düzel, Emrah; Yakupov, Renat; Dobisch, Laura; Metzger, Coraline D; Glanz, Wenzel; Ewers, Michael; Dechent, Peter; Haynes, John Dylan; Scheffler, Klaus; Roy, Nina; Rostamzadeh, Ayda; Teunissen, Charlotte E; Marchant, Natalie L.
  • Brosseron F; German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, Bonn 53127, Germany; Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, Venusberg-Campus 1, 53127 Bonn, Germany.
  • Maass A; German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, Magdeburg 39120, Germany.
  • Kleineidam L; German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, Bonn 53127, Germany; Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, Venusberg-Campus 1, 53127 Bonn, Germany.
  • Ravichandran KA; German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, Bonn 53127, Germany; Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, Venusberg-Campus 1, 53127 Bonn, Germany.
  • González PG; Research Center and Memory Clinic, Fundacío ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
  • McManus RM; German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, Bonn 53127, Germany; Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, Venusberg-Campus 1, 53127 Bonn, Germany.
  • Ising C; German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, Bonn 53127, Germany; Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, Venusberg-Campus 1, 53127 Bonn, Germany.
  • Santarelli F; German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, Bonn 53127, Germany; Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, Venusberg-Campus 1, 53127 Bonn, Germany.
  • Kolbe CC; University of Bonn Medical Center, Institute of Innate Immune, Venusberg-Campus 1, 53127 Bonn, Germany.
  • Häsler LM; Hertie Institute for Clinical Brain Research, Department of Cellular Neurology, University of Tübingen, Otfried-Müller-Strasse 27, 72076 Tübingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Otfried-Müller-Straße 27, Tübingen 72076, Germany.
  • Wolfsgruber S; German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, Bonn 53127, Germany; Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, Venusberg-Campus 1, 53127 Bonn, Germany.
  • Marquié M; Research Center and Memory Clinic, Fundacío ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
  • Boada M; Research Center and Memory Clinic, Fundacío ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
  • Orellana A; Research Center and Memory Clinic, Fundacío ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
  • de Rojas I; Research Center and Memory Clinic, Fundacío ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
  • Röske S; Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, Venusberg-Campus 1, 53127 Bonn, Germany.
  • Peters O; German Center for Neurodegenerative Diseases (DZNE), Charitéplatz 1, Berlin 10117, Germany; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 Berlin, Germany.
  • Cosma NC; German Center for Neurodegenerative Diseases (DZNE), Charitéplatz 1, Berlin 10117, Germany; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 Berlin, Germany.
  • Cetindag A; German Center for Neurodegenerative Diseases (DZNE), Charitéplatz 1, Berlin 10117, Germany; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 Berlin, Germany.
  • Wang X; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 Berlin, Germany.
  • Priller J; German Center for Neurodegenerative Diseases (DZNE), Charitéplatz 1, Berlin 10117, Germany; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 Berlin, Germany; Department of Psychiatry and Psychotherapy, Technical University Munich, 81675 Munich, Germany.
  • Spruth EJ; German Center for Neurodegenerative Diseases (DZNE), Charitéplatz 1, Berlin 10117, Germany; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 Berlin, Germany.
  • Altenstein S; German Center for Neurodegenerative Diseases (DZNE), Charitéplatz 1, Berlin 10117, Germany; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 Berlin, Germany.
  • Schneider A; German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, Bonn 53127, Germany; Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, Venusberg-Campus 1, 53127 Bonn, Germany.
  • Fliessbach K; German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, Bonn 53127, Germany; Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, Venusberg-Campus 1, 53127 Bonn, Germany.
  • Wiltfang J; German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, Göttingen 37075, Germany; Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, University of Göttingen, Von-Siebold-Str. 5, 37075 Göttingen, Germany; Neurosciences and Signaling Group, Institute of
  • Schott BH; German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, Göttingen 37075, Germany; Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, University of Göttingen, Von-Siebold-Str. 5, 37075 Göttingen, Germany; Leibniz Institute for Neurobiology, Brenneckestr
  • Bürger K; German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, Munich 81377, Germany; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Feodor-Lynen-Strasse 17, 81377 Munich, Germany.
  • Janowitz D; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Feodor-Lynen-Strasse 17, 81377 Munich, Germany.
  • Dichgans M; German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, Munich 81377, Germany; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Feodor-Lynen-Strasse 17, 81377 Munich, Germany.
  • Perneczky R; German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, Munich 81377, Germany; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany; Ageing Epidemiology Research Unit
  • Rauchmann BS; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Feodor-Lynen-Strasse 17, 81377 Munich, Germany.
  • Teipel S; German Center for Neurodegenerative Diseases (DZNE), Gehlsheimer Str. 20, Rostock 18147, Germany; Department of Psychosomatic Medicine, Rostock University Medical Center, Gehlsheimer Str. 20, 18147 Rostock, Germany.
  • Kilimann I; German Center for Neurodegenerative Diseases (DZNE), Gehlsheimer Str. 20, Rostock 18147, Germany; Department of Psychosomatic Medicine, Rostock University Medical Center, Gehlsheimer Str. 20, 18147 Rostock, Germany.
  • Goerss D; Department of Psychosomatic Medicine, Rostock University Medical Center, Gehlsheimer Str. 20, 18147 Rostock, Germany.
  • Laske C; German Center for Neurodegenerative Diseases (DZNE), Otfried-Müller-Straße 27, Tübingen 72076, Germany; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany.
  • Munk MH; German Center for Neurodegenerative Diseases (DZNE), Otfried-Müller-Straße 27, Tübingen 72076, Germany; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany.
  • Düzel E; German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, Magdeburg 39120, Germany; Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany.
  • Yakupov R; German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, Magdeburg 39120, Germany.
  • Dobisch L; German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, Magdeburg 39120, Germany; Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany.
  • Metzger CD; German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, Magdeburg 39120, Germany; Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany; Department of Psychiatry and Psychotherapy, Otto-von-Guericke University, Magdeburg, Ge
  • Glanz W; German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, Magdeburg 39120, Germany.
  • Ewers M; German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, Munich 81377, Germany.
  • Dechent P; MR-Research in Neurosciences, Department of Cognitive Neurology, Georg-August-University Göttingen, Göttingen, Germany.
  • Haynes JD; Bernstein Center for Computational Neurosciences, Charité - Universitätsmedizin, Berlin, Germany.
  • Scheffler K; Department for Biomedical Magnetic Resonance, University of Tübingen, 72076 Tübingen, Germany.
  • Roy N; German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, Bonn 53127, Germany.
  • Rostamzadeh A; Department of Psychiatry, University of Cologne, Medical Faculty, Kerpener Strasse 62, 50924 Cologne, Germany.
  • Teunissen CE; Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical centers, Vrije Universiteit, Amsterdam, the Netherlands.
  • Marchant NL; Division of Psychiatry, University College London, London, UK.
Neuron ; 110(6): 1009-1022.e4, 2022 03 16.
Article en En | MEDLINE | ID: mdl-34995486
There is an urgent need to improve the understanding of neuroinflammation in Alzheimer's disease (AD). We analyzed cerebrospinal fluid inflammatory biomarker correlations to brain structural volume and longitudinal cognitive outcomes in the DELCODE study and in a validation cohort of the F.ACE Alzheimer Center Barcelona. We investigated whether respective biomarker changes are evident before onset of cognitive impairment. YKL-40; sTREM2; sAXL; sTyro3; MIF; complement factors C1q, C4, and H; ferritin; and ApoE protein were elevated in pre-dementia subjects with pathological levels of tau or other neurodegeneration markers, demonstrating tight interactions between inflammation and accumulating neurodegeneration even before onset of symptoms. Intriguingly, higher levels of ApoE and soluble TAM receptors sAXL and sTyro3 were related to larger brain structure and stable cognitive outcome at follow-up. Our findings indicate a protective mechanism relevant for intervention strategies aiming to regulate neuroinflammation in subjects with no or subjective symptoms but underlying AD pathology profile.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer / Disfunción Cognitiva Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer / Disfunción Cognitiva Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article